查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年富血小板血浆治疗市场预测：按类型、来源、应用、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383484

2030 年富血小板血浆治疗市场预测：按类型、来源、应用、最终用户和地区进行的全球分析

Platelet-rich Plasma Therapy Market Forecasts to 2030 - Global Analysis By Type, Source, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球富血小板血浆治疗（PRP）市场规模将达7.1094亿美元，预测期内年复合成长率为14.97%，预计2030年将达到18.8765亿美元。

一种称为富血小板血浆疗法 (PRP) 的尖端医疗技术利用人体的自​​然癒合能力来刺激组织再生。在治疗过程中，抽取少量患者血液来浓缩血小板，血小板富含组织修復所需的生长因子和蛋白质。

根据美国红十字会的数据，PRP 为每 50 mL 5.5 x 10 血小板或更多。这意味着与全血相比，血小板浓度增加了 2-7 倍。人体血小板浓度的正常范围是每μL总静脉血150,000至450,000个。

对非手术和微创治疗的需求不断增加

随着越来越多的患者更喜欢停工时间较短、併发症风险较低的治疗方法，对非手术和微创治疗方法的需求正在增加。 PRP 疗法顺应了这一趋势，为皮肤再生、肌腱损伤和慢性关节疼痛等疾病提供侵入性较小的治疗方法。此外，利用身体自然癒合过程而不需要进行大量手术的概念对患者很有吸引力。

严格的保险保障

一个主要障碍是 PRP 治疗的保险范围有限。 PRP 治疗通常是自费治疗，这可能会阻碍一些对这种再生医学感兴趣的人。此外，缺乏广泛的保险支持可能导致它们难以获得和负担得起，从而限制了它们的采用，特别是在保险依赖度较高的地区。

扩大临床应用

一个有趣的前景是继续研究 PRP 治疗的新临床应用。确定 PRP 在先前未研究的疾病中的可再生可能是未来研究的重点。此外，进一步研究PRP在神经病学、心血管医学和自体免疫疾病等疾病中的功效可能会扩大PRP的潜在治疗效用。

科学共识不足

由于缺乏公认的定义或一套 PRP 製备和给药程序，损害了治疗的合法性。此外，不同的治疗参数和处理技术导致结果不一致，可能会使医疗保健提供者相互怀疑。为了应对这一威胁，必须透过研究和建立共识的努力建立统一的科学共识。

COVID-19 的影响：

富血小板血浆 (PRP) 治疗市场受到了 COVID-19大流行的各种影响。一方面，PRP 疗法的采用受到了由于卫生服务中断、关闭和应对大流行的资源重新分配而导致选择性和非紧急医疗程序暂时放缓的影响。然而，这场大流行凸显了再生医学的重要性，并更加重视以病人为中心的医学和微创手术。随着医疗保健系统的稳定，在新冠肺炎后的恢復期，对 PRP 治疗的需求应该会增加，特别是对于肌肉骨骼疾病和美容应用。

富含白血球和富含血小板的血浆（L-PRP）部分预计在预测期内是最大的

富含白血球的富含血小板的血浆（L-PRP）部分占最大份额。 L-PRP 的特征是白血球浓度高，被认为参与组织再生和免疫反应。白血球的发炎特性可能有助于治疗肌腱损伤和骨关节炎等疾病。此外，白血球被认为可以增强 PRP 的整体再生能力，使 L-PRP 在某些临床情况下成为有利的选择。 L-PRP 也用于口腔颚颜面外科。

预计美容医学领域在预测期内的年复合成长率最高。

在富血小板血浆（PRP）市场中，美容医疗领域预计年复合成长率最高。 PRP 疗法在美容医学中的使用急剧增加，特别是在美容皮肤科和脸部回春。 PRP 由于其可促进胶原蛋白生成和组织修復的再生特性，作为皮肤再生、皱纹减少和头髮修復的治疗方法而受到关注。此外，PRP 治疗是微创的，这符合非手术美容手术的日益普及。 PRP 在寻求持久自然美容解决方案的人们中越来越受欢迎，因为它以其均匀肤色、治疗脱髮和改善整体面部美观的能力而闻名。Masu。

占比最大的地区：

北美是富血小板血浆治疗（PRP）市场占有率最高的地区，也是该行业的主导地区。尤其美国，由于大量患者可以从再生治疗中受益、研发方面的大量投资以及发达的医疗基础设施等多种因素，对 PRP 市场的成长做出了重大贡献。此外，PRP治疗现已广泛应用于许多医学专业，包括整形外科、皮肤科和运动医学。这部分归因于该地区对医疗保健创新的关注和完善的法律规范。

复合年复合成长率最高的地区：

在富血小板血浆（PRP）市场成长方面，预计亚太地区的年复合成长率最高。随着世界人口老化、尖端医疗意识增强以及对整形外科美容的担忧增加，包括中国、日本、印度、印度等国家在内的亚太地区对再生医学的需求正在迅速增长。韩国，正在做。此外，PRP 疗法在肌肉骨骼疾病和运动医学领域也越来越受欢迎。此外，该地区在全球 PRP 市场中的重要性与日俱增，这是政府支持医疗基础设施发展的配合措施和对医疗旅游业日益关注的结果。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球富血小板血浆治疗 (PRP) 市场：按类型

  • 纯富血小板血浆 (P-PRP)
  • 富含白血球的富含血小板的血浆（L-PRP）
  • 纯血小板富含纤维蛋白 (P-PRF)
  • 富含白血球和富含血小板的纤维蛋白 (L-PRF)
  • 启动PRP
  • 自动调节血浆 (ACP)
  • 细胞PRP
  • 其他类型

第6章全球富血小板血浆治疗 (PRP) 市场：依来源分类

  • 自体的
  • 同种异体的
  • 其他来源

第7章全球富血小板血浆治疗 (PRP) 市场：依应用分类

  • 整形外科
  • 皮肤科
  • 牙科
  • 运动医学
  • 慢性伤口
  • 眼科
  • 美容医学
  • 心肌损伤
  • 其他用途

第8章全球富血小板血浆治疗 (PRP) 市场：按最终用户分类

  • 医院
  • 诊所
  • 研究和学术机构
  • 其他最终用户

第9章全球富血小板血浆治疗（PRP）市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Arthrex, Inc
  • Zimmer Biomet
  • EmCyte Corporation
  • Dr. PRP USA LLC
  • Juventix Regenerative Medical LLC
  • Johnson & Johnson Services, Inc.
  • Terumo Corporation
  • Stryker
  • Apex Biologix
  • Celling Biosciences, Inc
Product Code: SMRC24332

According to Stratistics MRC, the Global Platelet-rich Plasma Therapy (PRP) Market is accounted for $710.94 million in 2023 and is expected to reach $1887.65 million by 2030 growing at a CAGR of 14.97% during the forecast period. A state-of-the-art medical technique called platelet-rich plasma therapy (PRP) uses the body's own natural healing abilities to encourage tissue regeneration. In order to concentrate the platelets-which are abundant in growth factors and proteins necessary for tissue repair-a small amount of the patient's blood is extracted during the course of the treatment.

According to the American Red Cross, PRP is greater than or equal to 5.5 × 1010 platelets per 50 mL. This translates to a two- to sevenfold increase in platelet concentration compared with that of whole blood. The normal human range of platelet concentration is 150 000 to 450 000 platelets per µL of whole venous blood.

Market Dynamics:

Driver:

Growing need for non-surgical and low-invasive therapies

Patients' increasing preference for procedures with less downtime and a lower risk of complications is driving the demand for non-surgical and minimally invasive treatments. PRP therapy is in line with this trend by providing a less invasive treatment for ailments like skin rejuvenation, tendon injuries, and chronic joint pain. Additionally, the concept of utilizing the body's natural healing processes instead of requiring extensive surgery appeals to patients.

Restraint:

Strict insurance protection

The limited insurance provider coverage of PRP therapy is a major impediment. PRP treatment is frequently paid for by the patient, which may be a deterrent for some people interested in this regenerative medicine. Moreover, a lack of broad insurance support could make it more difficult to use and less affordable, which would restrict its adoption, especially in areas where people rely more heavily on insurance.

Opportunity:

Increasing the use of clinical applications

An interesting prospect is the continuous investigation of novel clinical uses for PRP therapy. Determining PRP's regenerative potential in diseases that haven't been studied before can be the focus of future research. Additionally, PRP's potential therapeutic utility may be expanded by further investigating its effectiveness in neurology, cardiovascular medicine, and autoimmune disorders, among other diseases.

Threat:

Insufficient scientific consensus

The legitimacy of the therapy is at risk since there is no accepted definition or set of procedures for the preparation and administration of PRP. Moreover, healthcare providers may become skeptical of one another if treatment parameters and processing techniques vary and produce inconsistent results. To counter this threat, a unified scientific consensus must be established through research and consensus-building efforts.

COVID-19 Impact:

The market for platelet-rich plasma (PRP) therapy has been impacted by the COVID-19 pandemic in a number of ways. On the one hand, the adoption of PRP therapy has been impacted by the temporary slowdown in elective and non-urgent medical procedures brought on by disruptions in healthcare services, lockdowns, and resource reallocation towards pandemic response. However, the pandemic has highlighted the significance of regenerative medicine, placing a greater focus on patient-centered care and minimally invasive procedures. As healthcare systems stabilize, there should be a rise in demand for PRP therapy in the post-COVID recovery period, particularly in musculoskeletal conditions and aesthetic applications.

The Leukocyte-rich Platelet-rich Plasma (L-PRP) segment is expected to be the largest during the forecast period

The segment leukocyte-rich platelet-rich plasma (L-PRP) holds the largest share. A higher concentration of white blood cells, which are thought to be involved in tissue regeneration and the immune response, is a characteristic of L-PRP. This particular segment is preferred in some medical applications, especially in orthopedics, where the anti-inflammatory characteristics of leukocytes may help treat ailments like tendon injuries and osteoarthritis. Moreover, leukocytes are assumed to augment PRP's overall regenerative capacity, rendering L-PRP favored option in particular clinical situations. L-PRP has also been used in oral and maxillofacial surgery.

The Aesthetic Medicine segment is expected to have the highest CAGR during the forecast period

In the platelet-rich plasma (PRP) market, the aesthetic medicine segment is projected to have the highest CAGR. PRP therapy use in aesthetic medicine has increased dramatically, especially in cosmetic dermatology and facial rejuvenation. PRP is a sought-after treatment for skin rejuvenation, wrinkle reduction, and hair restoration because of its regenerative qualities, which encourage collagen production and tissue repair. Additionally, PRP treatments are minimally invasive, which is in line with the rising popularity of non-surgical aesthetic procedures. PRP is becoming more and more popular among people looking for long-lasting, natural cosmetic solutions as a result of growing knowledge of its efficacy in improving skin texture, treating hair loss, and improving overall facial aesthetics.

Region with largest share:

With the largest market share for platelet-rich plasma (PRP), North America has been a dominant region in the industry. Due to a number of factors, including a highly prevalent patient population that can benefit from regenerative therapies, substantial investment in research and development, and an advanced healthcare infrastructure, the United States in particular has contributed significantly to the growth of the PRP market. Furthermore, PRP treatments are now widely used in many medical specialties, including orthopedics, dermatology, and sports medicine. This is due in part to the region's strong focus on technological innovation in healthcare and its well-established regulatory framework.

Region with highest CAGR:

In terms of platelet-rich plasma (PRP) market growth, the Asia-Pacific region is projected to have the highest CAGR. As the world's population ages and becomes more aware of cutting-edge medical treatments, as well as the increasing prevalence of orthopedic and cosmetic concerns, the Asia-Pacific region-which includes countries like China, Japan, India, and South Korea-is seeing a sharp increase in demand for regenerative medicine. Plus, PRP therapy is becoming more and more popular in the areas of musculoskeletal disorders and sports medicine. Moreover, the area's growing importance in the global PRP market is a result of government initiatives supporting the development of healthcare infrastructure as well as a growing focus on medical tourism.

Key players in the market

Some of the key players in Platelet-rich Plasma Therapy (PRP) market include: Arthrex, Inc, Zimmer Biomet, EmCyte Corporation, Dr. PRP USA LLC, Juventix Regenerative Medical LLC, Johnson & Johnson Services, Inc., Terumo Corporation, Stryker, Apex Biologix and Celling Biosciences, Inc.

Key Developments:

In June 2023, Dr. PRP USA LLC is proud to announce it has received 510K approval from the Food & Drug Administration (FDA) for its PRP kits. Now that the 510K clearance is final, Dr. PRP can continue to expand its market providing PRP kits to medical providers.

In May 2023, Zimmer Biomet Holdings, Inc., a global medical technology leader, announced it has reached a definitive agreement to acquire OSSIS, a privately-held medical device company that specializes in personalized 3D printed implants, as well as complex hip replacements, including second-time hip replacements and replacements involving bone tumors and trauma.

In January 2023, Arthrex, a global leader in minimally invasive surgical technology, announced its ACL TightRope implant has received clearance from the U.S. Food and Drug Administration (FDA) for pediatric indications. The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use.

Types Covered:

  • Pure-Platelet-rich Plasma (P-PRP)
  • Leukocyte-rich Platelet-rich Plasma (L-PRP)
  • Pure-Platelet-rich Fibrin (P-PRF)
  • Leukocyte-rich Platelet-rich Fibrin (L-PRF)
  • Activated PRP
  • Autologous Conditioned Plasma (ACP)
  • Cellular PRP
  • Other Types

Sources Covered:

  • Autologous
  • Allogenic
  • Other Sources

Applications Covered:

  • Orthopedics
  • Dermatology
  • Dental
  • Sports Medicine
  • Chronic Wounds
  • Ophthalmology
  • Aesthetic Medicine
  • Cardiac Muscle Injury
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Research and Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

,

5 Global Platelet-rich Plasma Therapy (prp) Market, By Type

  • 5.1 Introduction
  • 5.2 Pure-Platelet-rich Plasma (P-PRP)
  • 5.3 Leukocyte-rich Platelet-rich Plasma (L-PRP)
  • 5.4 Pure-Platelet-rich Fibrin (P-PRF)
  • 5.5 Leukocyte-rich Platelet-rich Fibrin (L-PRF)
  • 5.6 Activated PRP
  • 5.7 Autologous Conditioned Plasma (ACP)
  • 5.8 Cellular PRP
  • 5.9 Other Types

6 Global Platelet-rich Plasma Therapy (prp) Market, By Source

  • 6.1 Introduction
  • 6.2 Autologous
  • 6.3 Allogenic
  • 6.4 Other Sources

7 Global Platelet-rich Plasma Therapy (prp) Market, By Application

  • 7.1 Introduction
  • 7.2 Orthopedics
  • 7.3 Dermatology
  • 7.4 Dental
  • 7.5 Sports Medicine
  • 7.6 Chronic Wounds
  • 7.7 Ophthalmology
  • 7.8 Aesthetic Medicine
  • 7.9 Cardiac Muscle Injury
  • 7.10 Other Applications

8 Global Platelet-rich Plasma Therapy (prp) Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Research and Academic Institutes
  • 8.5 Other End Users

9 Global Platelet-rich Plasma Therapy (prp) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Arthrex, Inc
  • 11.2 Zimmer Biomet
  • 11.3 EmCyte Corporation
  • 11.4 Dr. PRP USA LLC
  • 11.5 Juventix Regenerative Medical LLC
  • 11.6 Johnson & Johnson Services, Inc.
  • 11.7 Terumo Corporation
  • 11.8 Stryker
  • 11.9 Apex Biologix
  • 11.10 Celling Biosciences, Inc

List of Tables

  • Table 1 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Pure-Platelet-rich Plasma (P-PRP) (2021-2030) ($MN)
  • Table 4 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Leukocyte-rich Platelet-rich Plasma (L-PRP) (2021-2030) ($MN)
  • Table 5 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Pure-Platelet-rich Fibrin (P-PRF) (2021-2030) ($MN)
  • Table 6 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Leukocyte-rich Platelet-rich Fibrin (L-PRF) (2021-2030) ($MN)
  • Table 7 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Activated PRP (2021-2030) ($MN)
  • Table 8 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Autologous Conditioned Plasma (ACP) (2021-2030) ($MN)
  • Table 9 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Cellular PRP (2021-2030) ($MN)
  • Table 10 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 11 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Source (2021-2030) ($MN)
  • Table 12 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Autologous (2021-2030) ($MN)
  • Table 13 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Allogenic (2021-2030) ($MN)
  • Table 14 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Sources (2021-2030) ($MN)
  • Table 15 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Orthopedics (2021-2030) ($MN)
  • Table 17 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Dermatology (2021-2030) ($MN)
  • Table 18 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Dental (2021-2030) ($MN)
  • Table 19 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Sports Medicine (2021-2030) ($MN)
  • Table 20 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Chronic Wounds (2021-2030) ($MN)
  • Table 21 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 22 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Aesthetic Medicine (2021-2030) ($MN)
  • Table 23 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Cardiac Muscle Injury (2021-2030) ($MN)
  • Table 24 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Research and Academic Institutes (2021-2030) ($MN)
  • Table 29 Global Platelet-rich Plasma Therapy (prp) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.